CSIMarket
 


Cure Pharmaceutical Holding Corp   (CURR)
Other Ticker:  
 
 

CURR's Income from Cont. Operations Growth by Quarter and Year

Cure Pharmaceutical Holding 's Income from Cont. Operations results by quarter and year




CURR Income from Cont. Operations (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 0.00 0.00 0.00
III Quarter September -2.79 0.00 0.00 0.00
II Quarter June -9.62 0.00 0.00 0.00
I Quarter March -5.15 0.00 0.00 0.00
FY   -17.56 0.00 0.00 0.00



CURR Income from Cont. Operations third quarter 2022 Y/Y Growth Comment
Cure Pharmaceutical Holding Corp in the third quarter 2022 recorded loss from continued operations of $ -2.79 millions.

According to the results reported in the third quarter 2022, Cure Pharmaceutical Holding Corp achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Cure Pharmaceutical Holding Corp ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the third quarter 2022.




CURR Income from Cont. Operations ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Cure Pharmaceutical Holding 's third quarter 2022 Income from Cont. Operations $ -2.79 millions CURR's Income Statement
Cure Pharmaceutical Holding 's third quarter 2021 Income from Cont. Operations $ 0.00 millions Quarterly CURR's Income Statement
New: More CURR's historic Income from Cont. Operations Growth >>


CURR Income from Cont. Operations (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Cure Pharmaceutical Holding 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CURR's III. Quarter Q/Q Income from Cont. Operations Comment
Although Cure Pharmaceutical Holding Corp in the III. Quarter 2022 admitted loss from continued operations of $ -2.79 millions, it should be mentioned, that current results are recovery relative to the -9.62 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Cure Pharmaceutical Holding Corp achieved highest sequential Income from Cont. Operations growth. While Cure Pharmaceutical Holding 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CURR's III. Quarter Q/Q Income from Cont. Operations Comment
Although Cure Pharmaceutical Holding Corp in the III. Quarter 2022 showed loss from continued operations of $ -2.79 millions, management point out, that those numbers show recovery relative to the -9.62 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Cure Pharmaceutical Holding Corp achieved highest sequential Income from Cont. Operations growth. While Cure Pharmaceutical Holding 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Cure Pharmaceutical Holding 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
Cumulative Income from Cont. Operations 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
In the Sep 30 2022 period, Cure Pharmaceutical Holding 's cumulative trailing twelve month Income from Cont. Operations remained unchanged compare to the same period a year ago.

Cure Pharmaceutical Holding Corp achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
In the Sep 30 2022 period, Cure Pharmaceutical Holding 's cumulative trailing twelve month Income from Cont. Operations remained unchanged compare to the same period a year ago.

Cure Pharmaceutical Holding Corp achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
CURR's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for CURR's Competitors
Income from Cont. Operations Growth for Cure Pharmaceutical Holding 's Suppliers
Income from Cont. Operations Growth for CURR's Customers

You may also want to know
CURR's Annual Growth Rates CURR's Profitability Ratios CURR's Asset Turnover Ratio CURR's Dividend Growth
CURR's Roe CURR's Valuation Ratios CURR's Financial Strength Ratios CURR's Dividend Payout Ratio
CURR's Roa CURR's Inventory Turnover Ratio CURR's Growth Rates CURR's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Sep 30 2022
Addus Homecare Corporation-0.29%$ -0.294 millions
Royalty Pharma Plc-0.62%$ -0.623 millions
Zoetis Inc -4.35%$ -4.348 millions
Henry Schein Inc -4.41%$ -4.410 millions
Charles River Laboratories International inc -7.18%$ -7.177 millions
Sotera Health Company-8.58%$ -8.577 millions
U S Physical Therapy Inc-9.22%$ -9.219 millions
Pediatrix Medical Group Inc -9.52%$ -9.523 millions
Ironwood Pharmaceuticals inc -9.90%$ -9.899 millions
Te Connectivity ltd -10.83%$ -10.831 millions
Semler Scientific inc -11.45%$ -11.446 millions
National Research Corporation-14.07%$ -14.073 millions
Lemaitre Vascular Inc-16.11%$ -16.113 millions
Intuitive Surgical Inc -16.14%$ -16.142 millions
Molecular Templates Inc -18.92%$ -18.919 millions
Regeneron Pharmaceuticals Inc -19.39%$ -19.391 millions
Universal Health Services Inc -19.40%$ -19.402 millions
Zynex inc -20.21%$ -20.206 millions
Progyny Inc -21.34%$ -21.344 millions
Khosla Ventures Acquisition Co -22.51%$ -22.507 millions
Tenax Therapeutics Inc -23.22%$ -23.222 millions
Maravai Lifesciences Holdings Inc -24.97%$ -24.966 millions
Reynolds Consumer Products Inc -27.27%$ -27.273 millions
Taitron Components Incorporated-28.61%$ -28.614 millions
Merck and Co Inc -28.83%$ -28.834 millions
Organon and Co -29.72%$ -29.721 millions
Gilead Sciences Inc -30.94%$ -30.936 millions
West Pharmaceutical Services Inc -31.32%$ -31.321 millions
Abbott Laboratories-31.67%$ -31.667 millions
Surgery Partners Inc -31.71%$ -31.707 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

SRAX's Profile

Stock Price

SRAX's Financials

Business Description

Fundamentals

Charts & Quotes

SRAX's News

Suppliers

SRAX's Competitors

Customers & Markets

Economic Indicators

SRAX's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071